6-Nitro-3-oxo-3,4-dihydropyrazine-2-carboxamide
CAS: 259793-97-0
Ref. 3D-JKA79397
| 1g | Discontinued | ||
| 5g | Discontinued | ||
| 10g | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- Pyrazinecarboxamide, 3,4-dihydro-6-nitro-3-oxo-
- 3,4-Dihydro-6-nitro-3-oxo-2-pyrazinecarboxamide
- 3-Hydroxy-6-nitro-2-pyrazinecarboxamide
- 2-Pyrazinecarboxamide, 3,4-dihydro-6-nitro-3-oxo-
Ravidasvir is a drug molecule that has been licensed for use in humans and is currently under development by Gilead Sciences. The drug has been shown to be effective against HIV-1, as well as hepatitis C virus (HCV). It is being tested as a possible treatment for chronic hepatitis B virus infection. Ravidasvir is a small molecule inhibitor of the viral protease enzyme, which prevents the release of new viruses from infected cells. Clinical trials have shown that ravidasvir can reduce both the amount of virus in patients' blood and the amount of virus in their semen. Covid-19, a drug containing ravidasvir, was approved by the FDA on December 18th, 2018. Gilead Sciences has filed patent applications for ravidasvir in more than 100 countries around the world.
